DelveInsight’s “Drug Delivery Devices- Market Insights, Competitive Landscape and Market Forecast–2030” report delivers a comprehensive analysis of the Drug Delivery Devices market, covering historical and forecasted potential patient pools, competitive landscape and market outlook across the globe through 2030.
Key Takeaways
-
Market size projection: As per DelveInsight’s analysis, the total drug delivery devices market size in the global market is expected to surge significantly by 2030, with an appreciable CAGR of 7.90% during the forecast period from 2024 to 2030.
-
Patient population data: The report provides the total drug delivery devices potential patient pool driven by the increasing chronic diseases prevalence such as diabetes, affecting 37.3 million people across the US in 2021, and cancer, with an estimated 2 million new cases diagnosed in the United States in 2020.
-
Key companies: Leading drug delivery devices companies, such as Pfizer Inc. (NYSE: PFE), Johnson & Johnson Services Inc. (NYSE: JNJ), Novartis AG (SIX Swiss Exchange: NOVN / NYSE: NVS), Boehringer Ingelheim, Medtronic Plc (NYSE: MDT), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NASDAQ: AZN), and Becton Dickinson (NYSE: BDX)., and others dominate the competitive landscape.
-
Pipeline assets: Some of the key drug delivery devices in the pipeline include injectable drug delivery systems, implantable drug delivery devices, inhalers and nebulizers, safety syringes, transdermal patches, and others across various therapeutic applications.
-
The FDA published updated guidance in August 2025 addressing human factors assessment requirements for injection devices, establishing comprehensive definitions for device classifications and user interface features. This regulatory framework significantly impacts generic injection device approvals through the ANDA pathway, requiring more rigorous usability testing.
-
In May 2025, two products employing Halozyme’s Enhanze drug delivery technology received FDA approval: BMS’s Opdivo and Johnson & Johnson’s DARZALEX FASPRO.
-
In December 2024, Coherus BioSciences received FDA approval for the UDENCYA ONBODY™ Injector, delivering pegfilgrastim-cbqv biosimilar for neutropenia treatment.
-
In July 2025, neffy® (epinephrine nasal spray) by ARS Pharmaceuticals became commercially available to patients at risk of anaphylaxis. This needle-free device represents the first FDA-approved nasal spray for emergency epinephrine delivery, offering a significant alternative to traditional auto-injectors for patients with needle phobia.
Recent tariff measures enacted in 2025 have introduced a baseline 10% duty on most Chinese imports affecting Drug Delivery Devices supply chains, with derivative tariffs of 25% on steel and aluminum components taking effect in March 2025. Know more about how the companies are navigating these tariff tensions @ Drug Delivery Devices Recent Developments.
Drug Delivery Devices Market Dynamics
The global drug delivery devices market demonstrates robust growth momentum, driven by multiple converging factors that collectively position the sector for sustained expansion through 2030. The market is experiencing a significant demand surge, primarily attributed to the escalating prevalence of chronic diseases worldwide, with diabetes and cancer serving as key therapeutic drivers requiring sophisticated delivery mechanisms.
This market momentum is fundamentally supported by the rising diabetic population, which necessitates reliable and precise drug delivery systems for effective disease management. The increasing frequency of both chronic and acute diseases, coupled with the expanding biologics market, creates substantial opportunities for advanced delivery technologies. The COVID-19 pandemic has positively influenced market dynamics, particularly through increased vaccination requirements and enhanced focus on efficient drug delivery systems for emergency healthcare responses.
The scientific rationale underlying drug delivery devices centers on optimizing therapeutic efficacy while minimizing adverse effects through controlled, targeted drug administration. Injectable delivery systems, in particular, offer significant advantages including predictable drug-release profiling, improved patient compliance, enhanced systemic availability by avoiding first-pass metabolism, reduced dosing frequency, and overall cost reduction in medical care. These systems are especially crucial for delivering larger molecules such as biologics, which require specialized administration methods due to their size, profile, and viscosity characteristics.
The drug delivery device competitive landscape reveals intense industry participation with established pharmaceutical giants and specialized device manufacturers pursuing strategic approaches to capture market share. Companies are focusing on technological advancements, regulatory approvals, and product innovation to maintain competitive positioning. North America dominates the market due to high chronic disease prevalence, robust research and development infrastructure, increasing biologics usage, and government initiatives supporting healthcare access.
The drug delivery device market challenges include stringent regulatory policies governing drug delivery devices and limited patient adoption in certain segments. However, opportunities abound through technological innovations, expanding applications across therapeutic areas, and growing demand for home-care medication delivery systems. Future outlook remains highly optimistic, with growth drivers including continued chronic disease burden, aging populations, advancement in biologics, and increasing preference for patient-friendly delivery mechanisms.
Download the Drug Delivery Devices Market report to understand which factors are driving the therapeutic market @ Drug Delivery Devices Market Trends.
Drug Delivery Devices Targeted Patient Pool
The drug delivery device patient pool is primarily driven by the global burden of chronic diseases requiring sophisticated therapeutic interventions across major markets. The disease burden encompasses multiple therapeutic areas, including oncology, diabetes, respiratory diseases, and infectious diseases, each contributing to the expanding patient population requiring advanced drug delivery solutions.
Diabetes represents a significant epidemiological driver, with the United States alone reporting 37.3 million affected individuals in 2021, accounting for approximately 11.3% of the total population. Of these cases, 28.7 million adults were formally diagnosed, highlighting the substantial treated patient population requiring continuous medication delivery systems. The oncological burden further amplifies market demand, with an estimated 1,806,590 new cancer cases diagnosed in the United States in 2020, alongside more than 600K patients affected by the disease during the same period.
Global cancer statistics indicate approximately 20 million cases worldwide in 2020, affecting more than 10 million people globally, demonstrating the extensive international patient pool requiring specialized drug delivery mechanisms. The total eligible patient pool encompasses individuals across various chronic conditions requiring long-term medication management, including respiratory diseases necessitating inhalation devices, oncology patients requiring injectable therapies, and diabetic populations utilizing multiple delivery modalities.
Geographic segmentation reveals North America as the dominant region due to high chronic disease prevalence, advanced healthcare infrastructure, and favorable regulatory environment supporting device adoption. The region’s epidemiological profile is characterized by significant diabetes and cancer burdens, driving substantial demand for sophisticated delivery systems. The forecast period extends through 2030, with epidemiological trends indicating continued growth in chronic disease prevalence, aging populations, and expanding diagnostic capabilities contributing to increased identification of treatable patient populations requiring advanced drug delivery solutions.
Discover evolving trends in the Drug Delivery Devices patient pool forecasts @ Drug Delivery Devices Patient Pool Analysis.
Key Drug Delivery Devices Companies and Treatment Market
The clinical and regulatory landscape for drug delivery devices is characterized by a comprehensive ecosystem of established pharmaceutical companies and specialized device manufacturers working to address diverse therapeutic needs across multiple administration routes. Current treatment options span implantable drug delivery devices, inhalers and nebulizers, safety syringes, transdermal patches, and various other delivery mechanisms designed to optimize therapeutic outcomes across oncology, infectious diseases, respiratory diseases, diabetes, and other therapeutic areas.
The drug delivery device clinical pipeline activity demonstrates robust development across multiple phases, with companies pursuing innovative delivery technologies to enhance patient outcomes and compliance. Key drug delivery device manufacturer include Pfizer Inc. (NYSE: PFE), Johnson & Johnson Services Inc. (NYSE: JNJ), F. Hoffmann-La Roche Ltd (SIX Swiss Exchange: ROG), Novartis AG (SIX Swiss Exchange: NOVN), 3M (NYSE: MMM), Bayer AG (Xetra: BAYN; ADR: BAYRY), uniQure N.V. (NASDAQ: QURE), Shenzhen Sibiono GeneTech Co. Ltd, Antares Pharma Inc. (NASDAQ: ATRS), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NASDAQ: AZN), Becton Dickinson (NYSE: BDX), Boehringer Ingelheim group, Consort Medical plc (Recipharm Group) (LSE: CSRT), Insulet Corporation (NASDAQ: PODD), Medtronic Plc (NYSE: MDT), Sulzer Ltd (SIX Swiss Exchange: SUR), West Pharmaceutical Services Inc (NYSE: WST), Generex Biotechnology (NASDAQ: GNBT), Panacea Pharmaceuticals Inc, Aptar Pharma (AptarGroup Inc., NYSE: ATR), Koninklijke Philips N.V. (Euronext Amsterdam: PHIA), Nemera, Biocorp Production, and Eli Lilly and Co. (NYSE: LLY), among others.
Market positioning varies across therapeutic applications, with injectable delivery systems commanding significant market share due to their effectiveness in delivering biologics and complex molecules. These systems offer superior drug-release profiling, enhanced patient compliance, and improved systemic availability compared to traditional oral formulations. Development milestones include strategic regulatory approvals such as the FDA clearance of AireHealth’s portable nebulizers in December 2020, B Braun’s Emergency Use Authorization for infusion pumps with nebulizers for COVID-19 treatment in April 2020, and the approval of GSK’s three-drug asthma inhaler in September 2020.
Commercial arrangements reflect increasing collaboration between pharmaceutical companies and device manufacturers to develop integrated therapeutic solutions. The market context emphasizes end-user applications across hospitals, ambulatory surgical centers, and home-care settings, with growing emphasis on patient-centric delivery mechanisms that enhance treatment adherence and clinical outcomes.
Delve deeper into the major and specialised companies in the Drug Delivery Devices market @ Drug Delivery Devices Competitive Landscape.
Conclusion
The drug delivery devices market represents a dynamic and rapidly expanding sector driven by increasing chronic disease prevalence, technological advancement, and growing demand for patient-friendly therapeutic solutions. With a projected CAGR of 7.90% through 2030, the market demonstrates strong fundamentals supported by robust pipeline activity, strategic regulatory approvals, and comprehensive industry participation across multiple therapeutic areas. The combination of favorable epidemiological trends, technological innovation, and expanding clinical applications positions the drug delivery devices market for sustained growth and continued therapeutic impact across global healthcare systems.
Table of Contents
1. Drug Delivery Devices Market Report Introduction
2. Drug Delivery Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Drug Delivery Devices Market Key Factors Analysis
6. Drug Delivery Devices Market Porter’s Five Forces Analysis
7. Drug Delivery Devices Market Assessment
8. Drug Delivery Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a leading business consulting and market research company focused on the healthcare and life sciences sectors, providing comprehensive market intelligence, competitive landscape analysis, and strategic insights to support decision-making across the pharmaceutical industry.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/